Royal London Asset Management
CAPR icon

Royal London Asset Management’s Capricor Therapeutics CAPR Stock Holding History

Royal London Asset Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-59,839
Closed -$1.98M – 644
2019
Q3 		$1.98M Buy
+59,839
New +$207K 0.02% 587

Other funds holding CAPR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Royal London Asset Management's CAPR Position: Q4 2019 in Review

Royal London Asset Management sold out of Capricor Therapeutics (CAPR) in Q4 2019, closing a stake of 59,839 shares — an estimated $1.98M sold.

Royal London Asset Management first reported a position in CAPR in Q3 2019 and held it in 1 quarter. The position peaked at $1.98M in Q3 2019. 17 funds tracked by Wall St. Rank hold CAPR as of Q4 2019.

  • Royal London Asset Management reported no remaining Capricor Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Royal London Asset Management sold 59,839 Capricor Therapeutics shares in Q4 2019, an estimated $1.98M.
  • Royal London Asset Management first reported a position in Capricor Therapeutics in Q3 2019 and held it in 1 quarter.
  • Royal London Asset Management's Capricor Therapeutics position peaked at $1.98M in Q3 2019.
  • 17 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2019.

Based on Royal London Asset Management's 13F filing for Q4 2019, filed 5 Feb 2020.